BioSpace News Archive

Cutera, Inc. (NASDAQ: CUTR ) (“Cutera” or the “Company”), a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, today reported financial results for the fourth quarter and full year ended December 31, 2020. Fourth Quarter 2020 Financial and Operational Highlights

Endo International plc announced that its Board of Directors has appointed Jennifer M. Chao to serve as a director, effective immediately.

AbCellera (NASDAQ: ABCL) will present at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 1:20 p.m. Pacific Time.

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, is scheduled to present at the following investor conferences: 10 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24 at 1:40 p.m. ET

Combined public entity to develop and commercialize next-generation immune therapies that address unmet needs in oncology, infectious disease, inflammation and auto-immune-mediated conditions FORT COLLINS, CO and BUFFALO, NY / ACCESSWIRE / February 17, 2021 / Cleveland BioLabs, Inc. (NASDAQ:CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system, filed a registration statement on Form S-4 (the “Registration Statement”) with the U

Albireo Pharma, Inc., a clinical-stage rare liver disease company developing novel bile acid modulators, announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common stock.

LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss, with an average reduction of 84.3% from baseline Achieved six of seven key secondary endpoints including reduction of pain Bone mineral density maintained at levels comparable to placebo Data were included in U.S. New Drug Application for relugolix combination tablet for uterine fibroids

Anita Boye is appointed as Senior Director of Azzur Labs Dallas, leading the organization’s newest analytical laboratory serving the biopharmaceutical and medical device industries

Boston Immune Technologies today announced that they have entered into an option and license agreement aimed at developing and commercializing BITT’s innovative tumor necrosis factor (TNF) receptor 2 (TNFR2) antagonist antibodies. BeiGene has secured an option to an exclusive license to develop, manufacture, and commercialize BITT’s proprietary TNFR2 antagonist antibodies in Asia (excluding Japan), Australia, and New Zealand.

Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (“Ortho”), one of the world’s largest pure-play in vitro diagnostics companies, today announced that S&P Global upgraded Ortho’s issuer credit rating to “B” from “B-” and Moody’s investment Services (“Moody’s”) upgraded Ortho’s Corporate Family Rating to “B1” from “B3.”